Rubius Therapeutics reports $32.6M loss in Q1

RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.
RUBIUS THERAPEUTICS reported a $32.6 million loss in the first quarter of 2019.
SMITHFIELD – Rubius Therapeutics Inc. reported a net loss of $32.6 million in the first quarter of 2019, or 42 cents per diluted share, compared with a $14.4 million loss, or $1.72 per diluted share, in the first quarter of 2018 according to a company filing Wednesday. The Cambridge, Mass., company, which specializes in allogenic…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -